-Developing combined anti-inflammatory and vasodilatory treatments for microvascular disease in chronic inflammatory disorders.
Gesynta Pharma is developing combined anti-inflammatory and vasodilatory treatments for microvascular diseases. Cardiovascular morbidity and mortality are common in chronic inflammatory diseases due to vascular inflammation and endothelial dysfunction. Our lead compound, GS-248, will prevent and treat these conditions by inhibiting the inducible enzyme mPGES-1. GS-248 is an orally available small molecule which will provide unique advantages over current standard of care and will enter Phase I in Q2 2019. The remaining non-clinical activities are fully funded, and we are currently looking to raise investment for the Phase I program and CMC activities needed to make GS-248 Phase II-ready.